Why health care is unaffordable – U.S. PIRG testimony for House Ways & Means Committee, Subcommittee on Health hearing:
Consumer group recommends solutions to high drug and hospital prices
Download the Testimony below
On March 23, 2023, the 13th anniversary of the Affordable Care Act, the House Ways & Means Committee’s Subcommittee on Health will host a hearing on health care affordability.
Patricia Kelmar, PIRG’s senior director for health care campaigns, has been selected to represent consumer interests with testimony at Thursday’s session. She will focus on how the prices of prescription drugs and hospital-based services have risen in the absence of competition in health markets and will discuss the solutions needed to constrain rising costs.
“The prices we are charged for prescription drugs and hospital care are the biggest drivers of our health care spending,” said Kelmar. “Employers and patients are paying higher and higher prices because health markets lack the competition that drives prices down. We need innovative solutions to end anticompetitive practices.”
Download U.S. PIRG’s testimony at the button to the left.
Watch a video of the hearing. Patricia’s testimony begins at 34:21.
Topics
Authors
Patricia Kelmar
Senior Director, Health Care Campaigns, PIRG
Patricia directs the health care campaign work for U.S. PIRG and provides support to our state offices for state-based health initiatives. Her prior roles include senior director of health policy with the National Consumers League, senior policy advisor at NJ Health Care Quality Institute, and advocate at AARP and NJPIRG. She serves on the Ground Ambulance and Patient Billing Advisory Committee at the Centers for Medicare and Medicaid Services. Patricia enjoys walks along the Potomac River and sharing her love of books with her friends and family around the world.
Find Out More
Testimony: Better resourced patent examination can improve drug price competition
Proliferation of medical credit cards raise concerns about increasing medical debt
The Cost of Prescription Drug Patent Abuse
